These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1089 related articles for article (PubMed ID: 32376954)

  • 1. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.
    Montagne A; Nation DA; Sagare AP; Barisano G; Sweeney MD; Chakhoyan A; Pachicano M; Joe E; Nelson AR; D'Orazio LM; Buennagel DP; Harrington MG; Benzinger TLS; Fagan AM; Ringman JM; Schneider LS; Morris JC; Reiman EM; Caselli RJ; Chui HC; Tcw J; Chen Y; Pa J; Conti PS; Law M; Toga AW; Zlokovic BV
    Nature; 2020 May; 581(7806):71-76. PubMed ID: 32376954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease.
    Halliday MR; Rege SV; Ma Q; Zhao Z; Miller CA; Winkler EA; Zlokovic BV
    J Cereb Blood Flow Metab; 2016 Jan; 36(1):216-27. PubMed ID: 25757756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-β in mild cognitive impairment but not in Alzheimer's disease.
    Xing F; Meng T; Therriault J; Luo J; Zhang H;
    J Integr Neurosci; 2021 Jun; 20(2):277-286. PubMed ID: 34258926
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Montagne A; Nikolakopoulou AM; Huuskonen MT; Sagare AP; Lawson EJ; Lazic D; Rege SV; Grond A; Zuniga E; Barnes SR; Prince J; Sagare M; Hsu CJ; LaDu MJ; Jacobs RE; Zlokovic BV
    Nat Aging; 2021 Jun; 1(6):506-520. PubMed ID: 35291561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.
    Nation DA; Sweeney MD; Montagne A; Sagare AP; D'Orazio LM; Pachicano M; Sepehrband F; Nelson AR; Buennagel DP; Harrington MG; Benzinger TLS; Fagan AM; Ringman JM; Schneider LS; Morris JC; Chui HC; Law M; Toga AW; Zlokovic BV
    Nat Med; 2019 Feb; 25(2):270-276. PubMed ID: 30643288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.
    Bell RD; Winkler EA; Singh I; Sagare AP; Deane R; Wu Z; Holtzman DM; Betsholtz C; Armulik A; Sallstrom J; Berk BC; Zlokovic BV
    Nature; 2012 May; 485(7399):512-6. PubMed ID: 22622580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
    Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
    JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing blood-brain barrier dysfunction and its association with Alzheimer's pathology, cognitive impairment and neuroinflammation.
    Preis L; Villringer K; Brosseron F; Düzel E; Jessen F; Petzold GC; Ramirez A; Spottke A; Fiebach JB; Peters O
    Alzheimers Res Ther; 2024 Jul; 16(1):172. PubMed ID: 39085945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
    Cicognola C; Mattsson-Carlgren N; van Westen D; Zetterberg H; Blennow K; Palmqvist S; Ahmadi K; Strandberg O; Stomrud E; Janelidze S; Hansson O
    Neurology; 2023 Jul; 101(1):e30-e39. PubMed ID: 37137722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Little genomic support for Cyclophilin A-matrix metalloproteinase-9 pathway as a therapeutic target for cognitive impairment in APOE4 carriers.
    Anderson EL; Williams DM; Walker VM; Davies NM
    Sci Rep; 2022 Jan; 12(1):1057. PubMed ID: 35058547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of Pericyte Damage in a Cognitively Normal Cohort: Association With CSF and PET Biomarkers of Alzheimer Disease.
    Haghdel A; Smith N; Glodzik L; Li Y; Wang X; Crowder T; Zhu YS; Butler T; Blennow K; McIntire LB; Pahlajani S; Osborne J; Chiang G; de Leon M; Ivanidze J
    Alzheimer Dis Assoc Disord; 2024 Apr-Jun 01; 38(2):107-111. PubMed ID: 38752577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?
    Femminella GD; Taylor-Davies G; Scott J; Edison P;
    J Alzheimers Dis; 2018; 64(3):981-993. PubMed ID: 29966204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Vascular Risk Factors on Blood-Brain Barrier and Cerebrospinal Fluid Biomarkers Along the Alzheimer's Disease Continuum: A Retrospective Observational Study.
    Ricci F; Martorana A; Bonomi CG; Serafini C; Mercuri NB; Koch G; Motta C
    J Alzheimers Dis; 2024; 97(2):599-607. PubMed ID: 38160356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
    Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals.
    Hong YJ; Kim CM; Lee JH; Sepulcre J
    Sci Rep; 2022 Aug; 12(1):14307. PubMed ID: 35995824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Aβ
    Wang HY; Trocmé-Thibierge C; Stucky A; Shah SM; Kvasic J; Khan A; Morain P; Guignot I; Bouguen E; Deschet K; Pueyo M; Mocaer E; Ousset PJ; Vellas B; Kiyasova V
    Alzheimers Res Ther; 2017 Jul; 9(1):54. PubMed ID: 28750690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
    Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
    J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.